Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL).

Next Previous
X
Search
Trial Profile

An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Follicular lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms MUNIN
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 26 Mar 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Nov 2012 Follow-up results will be presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition according to a Genmab media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top